Table 3.
Genotype frequency distribution among cases and controls for various combinations at rs8099917 in IL28B, rs1800470 and rs1800472 in TGF-β1, rs1042522 in TP53, rs180133 in MTHFR and rs1695 in GSTP1 and their possible association with Ischemic stroke.
| Genotype | Control | Case | OR (95 % CI) | Chi-Square value | P-value |
|---|---|---|---|---|---|
| TGF-β1rs1800470and IL28B rs8099917 | |||||
| TGF-β1 (CC) and IL28B (GG) | 35 | 23 | 1 (Ref) | ||
| TGF-β1(CC) IL28B (GT) | 4 | 9 | 3.42 (0.93 – 12.55) | ||
| TGF-β1(CC) IL28B (TT) | 18 | 16 | 0.39 (0.18 – 0.87) | ||
| TGF-β1 (CT) and IL28B (GG) | 17 | 16 | 1.05 (0.49 – 2.28) | ||
| TGF-β1 (CT) IL28B (GT) | 3 | 5 | 1.77 (0.40 – 7.77) | 10.328 | 0.243 |
| TGF-β1 (CT) IL28B (TT) | 7 | 15 | 1.28 (0.48 – 3.44) | ||
| TGF-β1(TT) and IL28B (GG) | 35 | 28 | 0.37 (0.19 – 0.73) | ||
| TGF-β1(TT) IL28B (GT) | 13 | 11 | 1.05 (0.44 – 2.53) | ||
| TGF-β1(TT) IL28B (TT) | 24 | 33 | 1.63 (0.85 – 3.13) | ||
| TGF-β1rs1800470and TP53 rs1042522 | |||||
| TGF-β1(CC) andTP53(CC) | 13 | 14 | 1 (Ref) | ||
| TGF-β1(CC) TP53 (GC) | 11 | 14 | 1.18 (0.41–3.39) | ||
| TGF-β1(CC) TP53 (GG) | 33 | 20 | 0.47 (0.18–1.19) | ||
| TGF-β1(CT) andTP53(CC) | 11 | 8 | 1.2 (0.37–3.84) | ||
| TGF-β1(CT) TP53 (GC) | 4 | 11 | 3.78 (0.97–14.74) | 18.208 | 0.02* |
| TGF-β1(CT) TP53 (GG) | 12 | 17 | 0.52 (0.18–1.48) | ||
| TGF-β1(TT) andTP53 (CC) | 16 | 20 | 0.88 (0.33–2.36) | ||
| TGF-β1(TT) TP53 (GC) | 14 | 28 | 1.6 (0.66–3.89) | ||
| TGF-β1(TT) TP53 (GG) | 42 | 24 | 0.29 (0.13–0.64) | ||
| TGF-β1rs1800470and TGF-β1rs1800472 | |||||
| TGF-β1(CC) and TGF-β1(CC) | 16 | 25 | 1 (Ref) | ||
| TGF-β1(CC) TGF-β1(CT) | 17 | 7 | 0.26 (0.09–0.74) | ||
| TGF-β1(CC) TGF-β1(TT) | 24 | 16 | 1.62 (0.64–4.12) | ||
| TGF-β1(CT) and TGF-β1(CC) | 7 | 25 | 5.35 (1.95–14.65) | 26.453 | 0.001*** |
| TGF-β1(CT) TGF-β1(CT) | 9 | 7 | 0.22 (0.07–0.72) | ||
| TGF-β1(CT) TGF-β1(TT) | 11 | 4 | 0.47 (0.13–1.68) | ||
| TGF-β1 (TT) and TGF-β1(CC) | 23 | 36 | 4.30 (1.74–10.61) | ||
| TGF-β1(TT) TGF-β1(CT) | 14 | 12 | 0.55 (0.20–1.54) | ||
| TGF-β1(TT) TGF-β1(TT) | 35 | 24 | 0.80 (0.37–1.74) | ||
| TGF-β1rs1800470and MTHFR rs180133 | |||||
| TGF-β1 (CC) and MTHFR(CC) | 14 | 21 | 1.00 (Ref) | ||
| TGF-β1 (CC) MTHFR (CT) | 5 | 9 | 1.20 (0.33–4.34) | ||
| TGF-β1 (CC) MTHFR (TT) | 38 | 18 | 0.32 (0.13–0.76) | ||
| TGF-β1 (CT) and MTHFR (CC) | 5 | 21 | 2.80 (0.85–9.17) | ||
| TGF-β1 (CT) MTHFR (CT) | 2 | 9 | 3.00 (0.56–16.01) | 43.24 | P < 0.001*** |
| TGF-β1 (CT) MTHFR (TT) | 20 | 6 | 0.20 (0.06–0.62) | ||
| TGF-β1 (TT) and MTHFR (CC) | 10 | 26 | 1.73 (0.64–4.69) | ||
| TGF-β1 (TT) MTHFR (CT) | 9 | 12 | 0.89 (0.30–2.66) | ||
| TGF-β1 (TT) MTHFR (TT) | 53 | 34 | 0.43 (0.19–0.95) | ||
| TGF-β1 rs1800470 and GSTP1 rs1695 | |||||
| TGF-β1 (CC) and GSTP1(AA) | 28 | 21 | 1 (Ref) | ||
| TGF-β1 (CC) GSTP1(AG) | 13 | 12 | 1.23 (0.47–3.24) | ||
| TGF-β1 (CC) GSTP1(GG) | 16 | 15 | 1.01 (0.41–2.49) | ||
| TGF-β1 (CT) and GSTP1(AA) | 18 | 16 | 0.95 (0.39–2.29) | ||
| TGF-β1 (CT) GSTP1(AG) | 1 | 9 | 10.10 (1.19–86.02) | 9.666 | 0.289 |
| TGF-β1 (CT) GSTP1(GG) | 8 | 11 | 0.15 (0.05–0.44) | ||
| TGF-β1 (TT) and GSTP1(AA) | 42 | 41 | 0.71 (0.35–1.45) | ||
| TGF-β1 (TT) GSTP1(AG) | 8 | 13 | 1.66 (0.58–4.73) | ||
| TGF-β1 (TT) GSTP1(GG) | 22 | 18 | 0.50 (0.22–1.16) | ||
| TGF-β1 rs1800472 and GSTP1 rs1695 | |||||
| TGF-β1(CC) and GSTP1(AA) | 26 | 40 | 1 (Ref) | ||
| TGF-β1(CC) GSTP1(AG) | 4 | 17 | 2.76 (0.83–9.13) | ||
| TGF-β1(CC) GSTP1(GG) | 16 | 29 | 0.43 (0.20–0.94) | ||
| TGF-β1(CT) and GSTP1(AA) | 24 | 16 | 0.36 (0.16–0.80) | ||
| TGF-β1(CT)GSTP1(AG) | 7 | 7 | 1.50 (0.47–4.78) | 26.142 | P < 0.001*** |
| TGF-β1(CT) GSTP1(GG) | 9 | 3 | 0.33 (0.08–1.33) | ||
| TGF-β1(TT) and GSTP1(AA) | 38 | 22 | 1.74 (0.85–3.58) | ||
| TGF-β1(TT) GSTP1(AG) | 11 | 10 | 1.57 (0.58–4.22) | ||
| TGF-β1(TT) GSTP1(GG) | 21 | 12 | 0.63 (0.27–1.50) | ||
| TGF-β1 rs1800472 and IL28B rs8099917 | |||||
| TGF-β1(CC) and IL28B (GG) | 20 | 34 | 1 (Ref) | ||
| TGF-β1(CC) IL28B (GT) | 7 | 14 | 1.18 (0.41–3.40) | ||
| TGF-β1(CC) IL28B (TT) | 19 | 38 | 1.18 (0.54–2.57) | ||
| TGF-β1(CT) and IL28B (GG) | 21 | 14 | 0.39 (0.16–0.94) | ||
| TGF-β1(CT) IL28B (GT) | 6 | 4 | 0.39 (0.10–1.56) | 26.531 | P < 0.001*** |
| TGF-β1(CT) IL28B (TT) | 13 | 8 | 0.36 (0.13–1.02) | ||
| TGF-β1(TT) and IL28B (GG) | 46 | 19 | 0.24 (0.11–0.52) | ||
| TGF-β1(TT) IL28B (GT) | 7 | 7 | 0.59 (0.18–1.92) | ||
| TGF-β1(TT) IL28B (TT) | 17 | 18 | 0.62 (0.26–1.48) | ||
| TGF-β1 rs1800472 and MTHFR rs180133 | |||||
| TGF-β1 (CC) and MTHFR(CC) | 9 | 42 | 1 (Ref) | ||
| TGF-β1 (CC) MTHFR (CT) | 7 | 17 | 0.52 (0.17–1.64) | ||
| TGF-β1 (CC) MTHFR (TT) | 30 | 27 | 0.37 (0.16–0.85) | ||
| TGF-β1 (CT) and MTHFR(CC) | 8 | 12 | 1.67 (0.56–4.94) | ||
| TGF-β1 (CT) MTHFR (CT) | 5 | 6 | 0.80 (0.21–3.05) | 50.335 | P < 0.001*** |
| TGF-β1 (CT) MTHFR (TT) | 27 | 8 | 0.25 (0.11–0.57) | ||
| TGF-β1 (TT) and MTHFR(CC) | 12 | 14 | 3.94 (1.39–11.15) | ||
| TGF-β1 (TT) MTHFR (CT) | 4 | 7 | 1.50 (0.39–5.75) | ||
| TGF-β1 (TT) MTHFR (TT) | 54 | 23 | 0.24 (0.13–0.46) | ||
| TGF-β1 rs1800472 and TP53 rs1042522 | |||||
| TGF-β1 (CC) andTP53 (CC) | 11 | 23 | 1 (Reference) | ||
| TGF-β1 (CC)TP53(GC) | 9 | 32 | 1.70 (0.64–4.49) | ||
| TGF-β1 (CC) TP53 (GG) | 27 | 31 | 0.32 (0.15–0.67) | 30.799 | P < 0.001*** |
| TGF-β1 (CT) andTP53 (CC) | 11 | 9 | 0.71 (0.25–2.00) | ||
| TGF-β1 (CT)TP53(GC) | 9 | 10 | 1.36 (0.47–3.91) | ||
| TGF-β1 (CT) TP53 (GG) | 20 | 7 | 0.32 (0.13–0.81) | ||
| TGF-β1 (TT) andTP53 (CC) | 18 | 10 | 1.59 (0.60–4.22) | ||
| TGF-β1 (TT) TP53 (GC) | 11 | 11 | 1.80 (0.64–5.08) | ||
| TGF-β1 (TT) TP53 (GG) | 40 | 23 | 0.58 (0.31–1.08) | ||
| TP53 rs1042522 and IL28B rs8099917 | |||||
| TP53 (CC) and IL28B (GG) | 24 | 18 | 1 (Ref) | ||
| TP53 (CC) IL28B (GT) | 5 | 6 | 1.6 (0.42–6.08) | ||
| TP53 (CC) IL28B (TT) | 9 | 18 | 1.67 (0.61–4.57) | ||
| TP53 (GC) and IL28B (GG) | 15 | 20 | 0.67 (0.27–1.66) | ||
| TP53 (GC) IL28B (GT) | 5 | 8 | 1.2 (0.34–4.29) | 16.975 | 0.03* |
| TP53 (GC) IL28B (TT) | 11 | 25 | 1.42 (0.56–3.62) | ||
| TP53 (GG) and IL28B (GG) | 49 | 29 | 0.26 (0.12–0.56) | ||
| TP53 (GG) IL28B (GT) | 10 | 11 | 1.86 (0.65–5.33) | ||
| TP53 (GG) IL28B (TT) | 28 | 21 | 0.68 (0.30–1.56) | ||
| TP53 rs1042522 and MTHFR rs180133 | |||||
| TP53 (CC) and MTHFR (CC) | 9 | 21 | 1 (Ref) | ||
| TP53 (CC) MTHFR (CT) | 3 | 11 | 1.57 (0.35–7.01) | ||
| TP53 (CC) MTHFR (TT) | 28 | 10 | 0.09 (0.03–0.26) | ||
| TP53 (GC) and MTHFR (CC) | 6 | 24 | 11.2 (3.42–36.72) | ||
| TP53 (GC) MTHFR (CT) | 6 | 9 | 0.38 (0.1–1.39) | 47.621 | P < 0.001*** |
| TP53 (GC) MTHFR (TT) | 17 | 20 | 0.78 (0.28–2.15) | ||
| TP53 (GG) and MTHFR (CC) | 14 | 23 | 1.39 (0.5–3.88)) | ||
| TP53 (GG) MTHFR (CT) | 7 | 10 | 0.87 (0.25–3.01) | ||
| TP53 (GG) MTHFR (TT) | 66 | 28 | 0.29 (0.12–0.71) | ||
| TP53 rs1042522 and GSTP1 rs1695 | |||||
| TP53 (CC) and GSTP1 (AA) | 22 | 21 | 1 (Ref) | ||
| TP53 (CC) GSTP1 (AG) | 4 | 13 | 3.4 (0.95–12.11) | ||
| TP53 (CC) GSTP1 (GG) | 14 | 8 | 0.17 (0.06–0.49) | ||
| TP53 (GC) and GSTP1 (AA) | 20 | 23 | 2.01 (0.86–4.69) | ||
| TP53 (GC) GSTP1 (AG) | 4 | 13 | 2.83 (0.79–10.08) | 22.771 | 0.004** |
| TP53 (GC) GSTP1 (GG) | 5 | 17 | 1.04 (0.33–3.33) | ||
| TP53 (GG) and GSTP1 (AA) | 46 | 34 | 0.22 (0.10–0.46) | ||
| TP53 (GG) GSTP1 (AG) | 14 | 8 | 0.77 (0.27–2.21) | ||
| TP53 (GG) GSTP1 (GG) | 27 | 19 | 1.23 (0.53–2.84) | ||
| IL28B rs 8099917 and GSTP1 rs1695 | |||||
| IL28B (GG) and GSTP1 (AA) | 54 | 41 | 1 (Ref) | ||
| IL28B (GG) GSTP1 (AG) | 9 | 7 | 1.02 (0.35–2.97) | ||
| IL28B (GG) GSTP1 (GG) | 24 | 19 | 1.01 (0.49–2.09) | ||
| IL28B (GT) and GSTP1 (AA) | 14 | 9 | 0.81 (0.32–2.05) | ||
| IL28B (GT) GSTP1 (AG) | 3 | 10 | 5.19 (1.34–20.07) | 11.615 | 0.169 |
| IL28B (GT) GSTP1 (GG) | 3 | 6 | 0.6 (0.14–2.54) | ||
| IL28B (TT) and GSTP1 (AA) | 20 | 28 | 0.7 (0.35–1.41) | ||
| IL28B (TT) GSTP1 (AG) | 10 | 17 | 1.21 (0.50–2.92) | ||
| IL28B (TT) GSTP1 (GG) | 19 | 19 | 0.59 (0.28–1.25) | ||
| IL28B rs8099917 and MTHFR rs180133 | |||||
| IL28B (GG) and MTHFR (CC) | 13 | 30 | 1 (Ref) | ||
| IL28B (GG) MTHFR (CT) | 10 | 12 | 0.52 (0.20–1.39) | ||
| IL28B (GG) MTHFR (TT) | 64 | 25 | 0.33 (0.16–0.69) | ||
| IL28B (GT) and MTHFR (CC) | 4 | 9 | 5.76 (1.63–20.39) | ||
| IL28B (GT) MTHFR (CT) | 1 | 5 | 2.22 (0.24–20.55) | 41.654 | P < 0.001*** |
| IL28B (GT) MTHFR (TT) | 15 | 11 | 0.15 (0.06–0.38) | ||
| IL28B (TT) and MTHFR (CC) | 12 | 29 | 3.29 (1.22–8.84) | ||
| IL28B (TT) MTHFR (CT) | 5 | 13 | 1.08 (0.33–3.48) | ||
| IL28B (TT) MTHFR (TT) | 32 | 22 | 0.26 (0.12–0.55 | ||
| MTHFR rs180133 and GSTP1 rs1695 | |||||
| MTHFR (CC) and GSTP1 (AA) | 17 | 33 | 1 (Ref) | ||
| MTHFR (CC) GSTP1 (AG) | 3 | 19 | 3.26 (0.83–12.78) | ||
| MTHFR (CC) GSTP1 (GG) | 9 | 16 | 0.28 (0.11–0.74) | ||
| MTHFR (CT) and GSTP1 (AA) | 12 | 12 | 0.56 (0.21–1.52) | ||
| MTHFR (CT) GSTP1 (AG) | 1 | 6 | 6.00 (0.67–53.55) | 43.102 | P < 0.001*** |
| MTHFR (CT) GSTP1 (GG) | 4 | 12 | 0.50 (0.14–1.77) | ||
| MTHFR (TT) and GSTP1 (AA) | 59 | 33 | 0.19 (0.09–0.40) | ||
| MTHFR (TT) GSTP1 (AG) | 19 | 9 | 0.85 (0.33–2.22) | ||
| MTHFR (TT) GSTP1 (GG) | 33 | 16 | 1.02 (0.46–2.29) | ||
P < 0.05 = Least significant (*); P < 0.01 = Significant (**); P < 0.001 =Highly significant (***): OR=Odd ratio; 95 % CI = 95 % confidence intervals